Home » Stocks » ALDX

Aldeyra Therapeutics, Inc. (ALDX)

Stock Price: $11.28 USD -0.29 (-2.51%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 536.29M
Revenue (ttm) n/a
Net Income (ttm) -37.55M
Shares Out 47.25M
EPS (ttm) -1.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $11.28
Previous Close $11.57
Change ($) -0.29
Change (%) -2.51%
Day's Open 11.49
Day's Range 10.90 - 11.53
Day's Volume 489,411
52-Week Range 2.50 - 14.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve...

1 month ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will discuss the potential of...

1 month ago - Business Wire

Aldeyra Therapeutics (ALDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, March 11, 2021 to report financial results for the year ended...

1 month ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will participate in analyst-l...

1 month ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will present at the 10th An...

2 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve...

2 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve...

2 months ago - Business Wire

Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company aiming to develop novel therapies for immune-mediated diseases with its lead candidate Reproxalap finishing up its Phase 3 multi-tria...

3 months ago - Seeking Alpha

Find out what led to the biotech industry's biggest gains.

Other stocks mentioned: LXRX, NCNA
3 months ago - The Motley Fool

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...

Other stocks mentioned: CAG, DMTK, FATE, GBIO, MRSN, ORI, REVG ...
3 months ago - Benzinga

The company announced the pricing of a public stock offering.

3 months ago - The Motley Fool

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve...

3 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve...

3 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fires...

3 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced positive top-line symptom, redness, and Schirmer's test results from the run-in cohort of the Phase...

3 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, January 7, 2021, to discuss top-line symptom, red...

3 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced confirmation of SARS-CoV-2 antiviral activity of ADX-1612, in addition to novel anti-inflammatory a...

3 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the initiation of Phase 2 clinical trials of ADX-629, a first-in-class orally administered reactive...

4 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve...

4 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the company's senior management will participate in the following virtual investor conferences...

5 months ago - Business Wire

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2020 Results - Quick Version Earnings Call Transcript

5 months ago - Seeking Alpha

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve...

5 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., will discuss Aldeyra's novel therapeutic approac...

5 months ago - Business Wire

Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX), a company focusing on immune-mediated diseases, are primed for further upside, according to a Jefferies analyst.  The Aldeyra Analyst: Kelly Shi initia...

5 months ago - Benzinga

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve...

5 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will present new data from the Phase 2 allergen chamber clinical trial of reproxalap ophtha...

5 months ago - Business Wire

An analyst is very bullish about the biotech stock.

6 months ago - The Motley Fool

Is (ALDX) Outperforming Other Medical Stocks This Year?

6 months ago - Zacks Investment Research

4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty

Other stocks mentioned: KMPH, NERV, SAVA
6 months ago - Zacks Investment Research

Is (ALDX) Outperforming Other Medical Stocks This Year?

7 months ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.

7 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.

7 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.

7 months ago - Business Wire

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: FLGT, NIU, PRIM, SURF
7 months ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.

7 months ago - Business Wire

Aldeyra Therapeutics: A New Cure To A Serious 21st Century Problem

7 months ago - Seeking Alpha

Week 35 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Other stocks mentioned: AAPL, CDXC, CVX, HD, INTC, JNJ, MRK ...
7 months ago - Seeking Alpha

Aldeyra Therapeutics, Inc. (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

8 months ago - Zacks Investment Research

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Aldeyra (ALDX) reports narrower-than-expected loss in the second quarter of 2020.

8 months ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.

8 months ago - Business Wire

Aldeyra's (ALDX) pipeline progress will be in focus when it reports Q2 results later in the week.

8 months ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.

8 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.

8 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with ...

9 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will discuss the company’s ...

9 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve...

9 months ago - Business Wire

Aldeyra Therapeutics, Inc. (ALDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

9 months ago - Zacks Investment Research

Aldeyra's Reproxalap Progress And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: ABBV, KZR
10 months ago - Seeking Alpha

About ALDX

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The compan... [Read more...]

Industry
Biotechnology
IPO Date
May 2, 2014
Stock Exchange
NASDAQ
Ticker Symbol
ALDX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for ALDX stock is "Strong Buy." The 12-month stock price forecast is 25.00, which is an increase of 121.63% from the latest price.

Price Target
$25.00
(121.63% upside)
Analyst Consensus: Strong Buy